Evidence map›Paper›PMID 41998764›Full record

ArticleMolecular cancer2026

MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression.

Guangzhao Pan, Qianqian Xu, Li Yuan, Lingling Wang, Che Zhang, Jiahan Le, Jing Zhao, Kui Zhang, Xin Hu, Hui Liang and 7 more

Abstract read
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Guangzhao Pan *Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Qianqian Xu *Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Li Yuan *Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Lingling WangCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Che ZhangCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Jiahan LeCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Jing ZhaoZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Kui ZhangPritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, IL, 60637, USA.
Xin HuJinfeng Laboratory, Chongqing, 401329, China.
Hui LiangCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Xiangliu ChenZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Jinyun DongCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Xiaoqing GuanZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Fangfang TaoZhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome, Zhejiang Chinese Medical University, China Collaborative Graduate School of Traditional Chinese Medicine, Hangzhou, Zhejiang, 310053, China.
Kai MiaoMOE Frontier Science Centre for Precision Oncology, University of Macau, Macau SAR, 999078, China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Jiang-Jiang QinCenter for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China. jqin@ucas.ac.cn.

Funding

Medical Science and Technology Project of Zhejiang Province WKJ-ZJ-2202National Natural Science Foundation of China 82203275Natural Science Foundation of Hangzhou 2025SZRJJ2312Natural Science Foundation of Zhejiang Province QKHM25H3103"Pioneer" and "Leading Goose" R&D Program of Zhejiang 2023SDYXS0001 & 2024SDYXS0003Program of Zhejiang Provincial TCM Sci-Tech Plan GZY-ZJ-KJ-24064Zhejiang Provincial People's Hospital-Hangzhou Institute of Medicine, Chinese Academy of Sciences Joint Research Fund 2025LHJJ03
6 · The paper itself

Abstract

Dynamic cytoskeletal homeostasis drives malignant transformation in tumor cells and represents a therapeutic vulnerability. Therapeutic targeting of this equilibrium may improve outcomes for cancer patients. Rac1 acts as a central molecular switch that controls actin cytoskeleton dynamics. Although multiple biological strategies modulate its spatiotemporal activity to maintain actin cytoskeleton homeostasis, the underlying molecular mechanisms remain unclear. Here, we identify FBXO44 as a critical regulator of Rac1 nucleocytoplasmic trafficking via its interaction with MTSS1. In gastric cancer (GC), FBXO44 directs two distinct ubiquitination programs on MTSS1: K63-linked polyubiquitination of MTSS1 promotes Rac1 nuclear translocation, whereas K11-linked polyubiquitination induces proteasomal degradation of MTSS1, restricting Rac1 nuclear entry. This ubiquitin-mediated coordination reprograms nucleocytoplasmic Rac1 signaling distribution and remodels the actin cytoskeleton. Structural analysis demonstrates that FBXO44 binds MTSS1 via distinct domains, dynamically balancing these opposing ubiquitination events by controlling MTSS1 abundance, thereby fine-tuning actin cytoskeletal dynamics. Clinically, this regulatory axis supports an oncogenic phenotype: FBXO44 overexpression correlates with enhanced Rac1 signaling and activation of associated pathways in advanced GC. Importantly, the expression balance of the FBXO44/MTSS1 axis significantly influences patient prognosis. Our findings provide mechanistic insights into cytoskeletal regulation and establish a translational framework for GC therapy.

Indexed as

Actin CytoskeletonF-Box ProteinsMicrofilament ProteinsStomach NeoplasmsUbiquitinAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceProtein Bindingrac1 GTP-Binding ProteinSignal TransductionUbiquitinationF-Box ProteinsMicrofilament Proteinsrac1 GTP-Binding ProteinRAC1 protein, humanUbiquitinActin cytoskeleton dynamicsFBXO44Gastric cancerMTSS1Rac1 signalingUbiquitin regulation

Identifiers

PMID41998764
PMCPMC13217682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.